The research bulletin
Private Peptides: a pencilled copy of the research
AOD-9604, MOTS-c and retatrutide, with the passages that deserve another look.
The passages beside the headline
A reassuring paper title can send a story in the wrong direction. AOD-9604 was well tolerated in its human trial program; the weight-loss endpoint failed. Circulating MOTS-c helped refine a risk model in dialysis patients; nobody in that study was given the peptide. Retatrutide produced a mean -24.2% body-weight change at 48 weeks; that figure describes one studied arm of a Phase 2 trial.
I prefer the questions scribbled beside those sentences to the slogans built from them. Why did the mouse result travel so badly? What exactly was measured in the human cohort? Which outcome would make the next retatrutide paper convincing? The small print has plenty of drama of its own.
A study can be reassuring about tolerability while disappointing about efficacy. AOD-9604 manages both.
AOD-9604: the obesity program
The growth-hormone fragment was designed to separate fat-metabolism activity from the hormone’s wider effects. Its story runs through animal experiments, human trials and an obesity program discontinued around 2007. The awkward ending earns more space here than the attractive mechanism.
MOTS-c: inside the cell
A peptide encoded within mitochondrial DNA goes to the nucleus under metabolic stress. That journey is stranger, and to my taste more interesting, than the longevity claims surrounding it. Cell and mouse experiments offer a busy scientific story; completed human efficacy trials of administered MOTS-c are absent from this record.
Retatrutide: separate outcomes
An engineered agonist at GLP-1, GIP and glucagon receptors has human trial results for body weight, blood glucose and liver fat. Those outcomes need their own subjects, time points and safety details. The obesity result impresses me; extending it to every other question drains away the specifics.
Read the retatrutide trials, or compare what the studies measured.